Purpose Studies regarding the relationship between age-related macular degeneration (AMD) and diabetic retinopathy (DR) conflict: while some support that AMD is protective against DR, others find the opposite. The mechanism by which AMD may protect against DR is unclear. We sought to assess the association between AMD and DR when controlling for glycemic control in patients with diabetes mellitus (DM) type II. Methods We identified 461 unique patients over 55 years old with a diagnosis of DM type II seen in our academic retina clinic in Stony Brook, New York between 12/31/2019 and 12/31/2020. Data were manually extracted and the population was split based on the presence of AMD diagnosis. Multivariate regression analyses were then performed comparing the prevalence of DR between groups while controlling for A1c. Secondary endpoints included demographic differences and smoking status.  Results Among the 461 patients, 118 (25.6%) had a diagnosis of AMD. Compared to patients without AMD, patients with AMD were older (69 vs. 66; OR 1.05; p=0.005) and less likely to have DR (37.3% vs. 59.2%; OR 0.35; p<0.001). There was no difference in average A1c between groups. Conclusion This is the first reported study assessing the relationship between AMD and DR while controlling for A1c. In our population, diagnosis of AMD was associated with significantly reduced odds of having DR. As AMD and DR appear to be related even after holding A1c constant, researchers should use caution when using DR as a surrogate for diabetic control in the context of AMD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560319PMC
http://dx.doi.org/10.7759/cureus.71479DOI Listing

Publication Analysis

Top Keywords

glycemic control
8
relationship age-related
8
age-related macular
8
macular degeneration
8
diabetic retinopathy
8
amd
8
patients amd
8
patients
5
adjusting glycemic
4
control assessing
4

Similar Publications

Background: Diabetes mellitus and periodontitis are two common chronic diseases with bidirectional relationship. Considering the role of oxidative stress in the pathogenesis of these two diseases, the use of nutritional supplements with antioxidant properties can be useful. The purpose of this study was to determine the effectiveness of daily synbiotic supplement in the management of patients with type 2 diabetes mellitus (T2DM) and periodontal disease (PD) under non-surgical periodontal therapy (NSPT).

View Article and Find Full Text PDF

[Glucokinase activators and imeglimin: New drugs against type 2 diabetes].

Lakartidningen

January 2025

professor, överläkare, VO internmedicin, sektionen för diabetologi och endokrinologi, Gävle sjukhus; Centrum för forskning och utveckling, Uppsala universitet/Region Gävleborg.

Type 2 diabetes (T2D) is increasing relentlessly globally, affecting ever younger patients. Many T2D patients do not attain glycemic target levels, indicating a clear need for novel antihyperglycemic drugs. Ideally, these should not only control glycemia, but also halt or slow the progressive loss of beta cells.

View Article and Find Full Text PDF

This study evaluates the effects of liraglutide on albuminuria, oxidative stress, and inflammation in type 2 diabetes (T2D) patients with different urinary albumin-to-creatinine ratio (UACR) categories. We enrolled 107 patients with T2D who were initiating liraglutide for glycemic control. Patients were categorized into 3 groups: group I (UACR < 30 mg/g); group II (30 mg/g ≤ UACR ≤ 300 mg/g); group III (UACR > 300 mg/g).

View Article and Find Full Text PDF

Obesity is considered an important factor contributing to the development of atherosclerosis. Inflammation plays a key role in endothelial dysfunction (ED), an initial stage of the atherosclerotic process. Several microRNAs (miRNAs) may play an important role in the inflammatory process, but there is a lack of information about their participation in the early stages of atherosclerosis development in patients with obesity.

View Article and Find Full Text PDF

Purpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. This study aimed to investigate the efficacy of combining imeglimin with dipeptidyl peptidase-4 inhibitor (DPP-4i), the most frequently prescribed first-line treatment for patients with type 2 diabetes (T2D) in Japan, to improve glycemic control.

Patients And Methods: Eleven patients with T2D treated with DPP-4i alone (6.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!